X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-05 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $61.93 | -15,000 | 50,440 | -23% | -$928,950 | |||||
| DM | 2026-02-03 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $41.39 | -13,180 | 65,640 | -17% | -$545,473 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Coric Vlad | Dir | P - Purchase | $17.00 | +117,646 | 449,337 | +35% | +$1,999,982 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Childs John W | Dir | P - Purchase | $17.00 | +294,117 | 2,202,006 | +15% | +$4,999,989 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Longitude Capital Partners V, LLC | 10% | P - Purchase | $17.00 | +1,075,000 | 2,053,474 | +110% | +$18,275,000 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Enright Patrick G | Dir, 10% | P - Purchase | $17.00 | +1,075,000 | 2,053,474 | +110% | +$18,275,000 | |||||
| D | 2026-02-03 | PMN | Promis Neurosciences Inc. | Abg Management Ltd. | 10% | P - Purchase | $12.13 | +700,741 | 943,090 | +289% | +$8,499,988 | |||||
| D | 2026-02-03 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $40.87 | -20,000 | 1,235 | -94% | -$817,334 | |||||
| D | 2026-02-05 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $483.25 | -8,300 | 36,781 | -18% | -$4,010,940 | |||||
2026-02-03 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $14.94 | -4,170 | 162,894 | -2% | -$62,305 | ||||||
2026-02-04 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $6.69 | -970 | 612,919 | 0% | -$6,489 | ||||||
2026-02-04 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale | $32.21 | -1,779 | 105,706 | -2% | -$57,295 | ||||||
2026-02-04 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $32.19 | -1,745 | 111,226 | -2% | -$56,168 | ||||||
2026-01-30 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale | $82.93 | -6,179 | 48,065 | -11% | -$512,446 | ||||||
| D | 2026-02-02 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $33.93 | -9,000 | 57,740 | -13% | -$305,385 | |||||
2026-01-30 | IONS | Ionis Pharmaceuticals Inc | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S - Sale | $83.45 | -6,179 | 69,702 | -8% | -$515,630 | ||||||
2026-01-30 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale | $83.53 | -6,179 | 71,983 | -8% | -$516,153 | ||||||
2026-01-30 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale | $82.72 | -62,970 | 283,927 | -18% | -$5,208,979 | ||||||
2026-01-30 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale | $83.03 | -6,179 | 66,247 | -9% | -$513,048 | ||||||
2026-01-30 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale | $82.95 | -5,885 | 100,293 | -6% | -$488,141 | ||||||
2026-01-30 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale | $82.96 | -5,296 | 50,185 | -10% | -$439,364 | ||||||
| D | 2026-02-02 | ALKS | Alkermes Plc. | Cooke Shane | Dir | S - Sale+OE | $34.57 | -61,200 | 103,744 | -37% | -$2,115,673 | |||||
2026-02-02 | ABEO | Abeona Therapeutics Inc. | Wuchterl Donald A. | Dir | S - Sale | $5.09 | -14,814 | 167,935 | -8% | -$75,412 | ||||||
2026-02-02 | ABEO | Abeona Therapeutics Inc. | Crombez Eric | Dir | S - Sale | $5.09 | -16,284 | 63,456 | -20% | -$82,895 | ||||||
| D | 2026-02-02 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $185.60 | -32,410 | 7,351,729 | 0% | -$6,015,296 | |||||
| D | 2026-02-02 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale+OE | $7.45 | -16,667 | 1,243,174 | -1% | -$124,147 | |||||
| D | 2026-01-30 | ZVRA | Zevra Therapeutics, Inc. | Sangiovanni Timothy J. | SVP, Finance, Corp Controller | S - Sale+OE | $8.82 | -1,750 | 32,590 | -5% | -$15,442 | |||||
| D | 2026-01-30 | ZVRA | Zevra Therapeutics, Inc. | Thompson Rahsaan | Chief Legal, Compliance | S - Sale+OE | $8.83 | -4,080 | 49,919 | -8% | -$36,010 | |||||
| D | 2026-01-30 | ZVRA | Zevra Therapeutics, Inc. | Quartel Adrian W | Chief Medical Officer | S - Sale+OE | $8.83 | -4,533 | 9,723 | -32% | -$40,036 | |||||
| D | 2026-01-30 | ZVRA | Zevra Therapeutics, Inc. | Schafer Joshua | CCO | S - Sale+OE | $8.83 | -3,375 | 72,778 | -4% | -$29,800 | |||||
| D | 2026-02-02 | ZVRA | Zevra Therapeutics, Inc. | McFarlane Neil F. | Pres, CEO | S - Sale+OE | $9.38 | -91,000 | 364,350 | -20% | -$853,425 | |||||
| M | 2026-01-29 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.23 | -24,770 | 555,559 | -4% | -$104,862 | |||||
2026-01-30 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $41.09 | -20,000 | 26,418 | -43% | -$821,810 | ||||||
| D | 2026-02-02 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $62.10 | -886 | 50,440 | -2% | -$55,021 | |||||
| D | 2026-01-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $102.08 | -5,500 | 58,117 | -9% | -$561,422 | |||||
2026-02-02 | ABEO | Abeona Therapeutics Inc. | Alland Leila | Dir | S - Sale | $5.09 | -18,065 | 173,614 | -9% | -$91,962 | ||||||
2026-02-02 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.09 | -2,000 | 84,065 | -2% | -$10,181 | ||||||
| M | 2026-01-29 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.11 | -13,465 | 48,820 | -22% | -$540,037 | |||||
| D | 2026-01-30 | APRE | Aprea Therapeutics, Inc. | Gilad Oren | Pres, CEO | P - Purchase | $0.89 | +28,100 | 375,520 | +8% | +$25,009 | |||||
| D | 2026-01-30 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | SrVP, CFO, Prin Fin, Acct Ofcr | P - Purchase | $0.89 | +5,700 | 33,433 | +21% | +$5,073 | |||||
| M | 2026-01-28 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $18.49 | -34,398 | 396,945 | -8% | -$635,857 | |||||
| D | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $16.60 | -3,661 | 45,427 | -7% | -$60,767 | |||||
| D | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $16.60 | -4,421 | 57,010 | -7% | -$73,381 | |||||
| D | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $16.60 | -4,895 | 83,672 | -6% | -$81,249 | |||||
| D | 2026-01-28 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | S - Sale+OE | $14.18 | -3,611 | 0 | -100% | -$51,188 | |||||
2026-01-28 | AIMD | Ainos, Inc. | Taiwan Carbon Nano Technology Corp | 10% | S - Sale | $2.17 | -46,000 | 989,925 | -4% | -$99,806 | ||||||
2026-01-28 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $7.03 | -50 | 22,622 | 0% | -$352 | ||||||
| DM | 2026-01-27 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $32.25 | -72,428 | 24,353 | -75% | -$2,335,860 | |||||
2026-01-27 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $57.05 | +100 | 459,944 | 0% | +$5,705 | ||||||
| D | 2026-01-28 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.57 | -6,500 | 0 | -100% | -$23,186 | |||||
2026-01-28 | ANIX | Anixa Biosciences Inc | Baskies Arnold M | Dir | P - Purchase | $3.04 | +10,000 | 135,000 | +8% | +$30,400 | ||||||
2026-01-26 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | CFO | S - Sale | $37.15 | -3,746 | 24,521 | -13% | -$139,171 | ||||||
| DM | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Bharucha David | Chief Medical Officer | S - Sale+OE | $2.25 | -70,252 | 113,181 | -38% | -$158,209 | |||||
| DM | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Nelson Jeffrey Edward | COO | S - Sale+OE | $2.25 | -70,252 | 49,848 | -58% | -$158,209 | |||||
| DM | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Muller Lorenz | Chief Commercial Officer | S - Sale+OE | $2.25 | -64,746 | 205,406 | -24% | -$145,851 | |||||
| DM | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Hasija Amit | CFO, EVP of Corp. Development | S - Sale+OE | $2.25 | -70,252 | 99,848 | -41% | -$158,209 | |||||
| DM | 2025-12-15 | MIST | Milestone Pharmaceuticals Inc. | Oliveto Joseph | Pres, CEO | S - Sale+OE | $2.24 | -167,577 | 482,744 | -26% | -$375,315 | |||||
2026-01-26 | JNJ | Johnson & Johnson | Duato Joaquin | CEO, COB | S - Sale | $221.23 | -100,000 | 307,807 | -25% | -$22,122,893 | ||||||
| M | 2026-01-26 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.98 | -19,274 | 580,329 | -3% | -$96,045 | |||||
| DM | 2026-01-20 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $470.03 | -30,375 | 2,648 | -92% | -$14,277,114 | |||||
2026-01-26 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $41.65 | -1,580 | 178,848 | -1% | -$65,807 | ||||||
| D | 2026-01-20 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $464.66 | -14,625 | 2,648 | -85% | -$6,795,627 | |||||
2026-01-26 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale | $41.65 | -688 | 211,169 | 0% | -$28,655 | ||||||
2026-01-27 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $8.46 | -6,414 | 183,275 | -3% | -$54,266 | ||||||
2026-01-27 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $8.46 | -1,813 | 153,560 | -1% | -$15,339 | ||||||
2026-01-27 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $8.46 | -8,180 | 267,274 | -3% | -$69,209 | ||||||
2026-01-27 | KURA | Kura Oncology, Inc. | Doyle Thomas James | SVP, Finance, Accounting | S - Sale | $8.46 | -7,142 | 145,667 | -5% | -$60,426 | ||||||
2026-01-27 | KURA | Kura Oncology, Inc. | Burrows Francis | Chief Scientific Officer | S - Sale | $8.46 | -1,311 | 32,424 | -4% | -$11,092 | ||||||
2026-01-27 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $8.46 | -11,208 | 226,931 | -5% | -$94,828 | ||||||
| DM | 2026-01-23 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale+OE | $84.18 | -48,273 | 574,505 | -8% | -$4,063,743 | |||||
| D | 2026-01-27 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale+OE | $83.13 | -46,203 | 60,320 | -43% | -$3,841,037 | |||||
| DM | 2026-01-23 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale+OE | $82.30 | -23,151 | 84,115 | -22% | -$1,905,305 | |||||
| DM | 2026-01-23 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $30.09 | -60,000 | 419,173 | -13% | -$1,805,134 | |||||
| DM | 2026-01-23 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $33.29 | -72,572 | 24,353 | -75% | -$2,415,843 | |||||
| D | 2026-01-26 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $96.19 | -1,053 | 43,741 | -2% | -$101,290 | |||||
| D | 2026-01-26 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Pres, COO | S - Sale+OE | $96.19 | -3,143 | 23,286 | -12% | -$302,331 | |||||
| D | 2026-01-26 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $96.19 | -842 | 3,700 | -19% | -$80,994 | |||||
| D | 2026-01-26 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $96.19 | -6,831 | 356,902 | -2% | -$657,088 | |||||
| D | 2026-01-23 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $40.55 | -1,235 | 62,285 | -2% | -$50,084 | |||||
2026-01-23 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Dir | P - Purchase | $68.48 | +131,425 | 4,031,625 | +3% | +$8,999,984 | ||||||
2026-01-26 | MDGL | Madrigal Pharmaceuticals, Inc. | Huntsman Carole | Chief Commercial Officer | S - Sale | $493.78 | -910 | 9,122 | -9% | -$449,339 | ||||||
2026-01-22 | SION | Sionna Therapeutics, Inc. | Tpg Gp A, LLC | 10% | S - Sale | $40.00 | -250,000 | 6,494,962 | -4% | -$10,000,000 | ||||||
2026-01-26 | MDGL | Madrigal Pharmaceuticals, Inc. | Sibold William John | Pres, CEO | S - Sale | $492.42 | -1,577 | 148,497 | -1% | -$776,546 | ||||||
2026-01-26 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale | $492.42 | -647 | 1,108,244 | 0% | -$318,596 | ||||||
2026-01-22 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Chief Commercial Officer | S - Sale | $5.29 | -12,610 | 318,619 | -4% | -$66,658 | ||||||
2026-01-22 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale | $18.10 | -3,828 | 210,164 | -2% | -$69,296 | ||||||
| D | 2026-01-22 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.15 | -1,882 | 145,355 | -1% | -$34,162 | |||||
2026-01-23 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $40.26 | -20,000 | 46,418 | -30% | -$805,110 | ||||||
2026-01-23 | ABT | Abbott Laboratories | Ford Robert B | COB, CEO | P - Purchase | $107.13 | +18,800 | 469,508 | +4% | +$2,013,967 | ||||||
| D | 2026-01-22 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | CFO | S - Sale+OE | $187.92 | -12,000 | 43,076 | -22% | -$2,255,040 | |||||
| D | 2026-01-21 | AXSM | Axsome Therapeutics, Inc. | Maizel Ari | Chief Commercial Officer | S - Sale+OE | $184.44 | -7,500 | 0 | -100% | -$1,383,300 | |||||
2026-01-22 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale | $81.34 | -3,977 | 22,541 | -15% | -$323,490 | ||||||
| M | 2026-01-22 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $56.36 | +3,324 | 459,844 | +1% | +$187,356 | |||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale | $72.45 | -4,895 | 31,599 | -13% | -$354,643 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Pres, CEO | S - Sale | $72.45 | -14,387 | 269,007 | -5% | -$1,042,338 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Chief Scientific Officer | S - Sale | $72.45 | -6,534 | 85,093 | -7% | -$473,388 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale | $72.45 | -4,542 | 59,290 | -7% | -$329,068 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale | $72.45 | -1,758 | 170,434 | -1% | -$127,367 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale | $72.45 | -2,929 | 113,938 | -3% | -$212,206 | ||||||
| M | 2026-01-22 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $5.30 | -18,221 | 599,603 | -3% | -$96,658 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |